These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11660326)

  • 1. Guidelines for relationships between industry and the American College of Obstetricians and Gynecologists and its fellows. ACOG Committee Opinion No. 45.
    American College of Obstetricians and Gynecologists [ACOG]. Committee on Ethics
    ACOG Comm Opin; 1985 Oct; No. 45():1 p. PubMed ID: 11660326
    [No Abstract]   [Full Text] [Related]  

  • 2. General Council to consider amendments to CMA policy on MDs' relationships with drug industry.
    Williams JR
    CMAJ; 1993 Aug; 149(3):335-7. PubMed ID: 11659649
    [No Abstract]   [Full Text] [Related]  

  • 3. Guidelines on gifts to physicians from industry: an update.
    American Medical Association. Council on Ethical and Judicial Affairs
    Food Drug Law J; 1992; 47(4):445-58. PubMed ID: 11654909
    [No Abstract]   [Full Text] [Related]  

  • 4. AMA's gift guidelines.
    Conley RB
    Food Drug Cosmet Med Device Law Dig; 1993; 10():19-27. PubMed ID: 11654936
    [No Abstract]   [Full Text] [Related]  

  • 5. The CMA's MD-drug industry guidelines offer advice, nothing more.
    Woollard R
    CMAJ; 1991 Dec; 145(11):1498-9. PubMed ID: 11649304
    [No Abstract]   [Full Text] [Related]  

  • 6. CMA guidelines concerning relationship of MDs and drug industry to be revised, board told.
    Sullivan P
    CMAJ; 1993 Jan; 148(2):273-5. PubMed ID: 11652162
    [No Abstract]   [Full Text] [Related]  

  • 7. CMA guidelines on MD-drug industry relations part of international trend.
    Williams JR
    CMAJ; 1992 Feb; 146(3):386-8. PubMed ID: 11654902
    [No Abstract]   [Full Text] [Related]  

  • 8. Two cheers for the CMA's new guidelines on drug company-MD relations The CMA's MD-drug industry guidelines offer advice, nothing more.
    Rapp MS; Woollard R
    CMAJ; 1991 Dec; 145(11):1497-9. PubMed ID: 11649303
    [No Abstract]   [Full Text] [Related]  

  • 9. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry--self-regulation in the shadow of federal prosecution.
    Studdert DM; Mello MM; Brennan TA
    N Engl J Med; 2004 Oct; 351(18):1891-900. PubMed ID: 15509824
    [No Abstract]   [Full Text] [Related]  

  • 10. Ethical responsibilities of physicians in their dealings with pharmaceutical companies.
    Royal College of Physicians and Surgeons of Canada. Biomedical Ethics Committee
    Ann R Coll Physicians Surg Can; 1990 Jan; 23(1):45-8. PubMed ID: 11650305
    [No Abstract]   [Full Text] [Related]  

  • 11. Physicians and the pharmaceutical industry.
    Canadian Medical Association
    CMAJ; 1992 Feb; 146(3):388A-C. PubMed ID: 11654903
    [No Abstract]   [Full Text] [Related]  

  • 12. Guidelines for interactions with pharmaceutical companies.
    American Medical Association. Resident Physicians Section
    JAMA; 1993 Sep; 270(10):1250. PubMed ID: 11643149
    [No Abstract]   [Full Text] [Related]  

  • 13. Ethical guidance for patient testing. ACOG Committee Opinion No. 159.
    American College of Obstetricians and Gynecologists. Committee on Ethics
    ACOG Comm Opin; 1995 Oct; No. 159():3 p. PubMed ID: 11660416
    [No Abstract]   [Full Text] [Related]  

  • 14. Conflicts of interest between physicians and the pharmaceutical industry and special interest groups.
    Schetky DH
    Child Adolesc Psychiatr Clin N Am; 2008 Jan; 17(1):113-25, ix-x. PubMed ID: 18036482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost containment in medical care. ACOG Committee Opinion No. 171.
    American College of Obstetricians and Gynecologists [ACOG]. Committee on Practice Management
    ACOG Comm Opin; 1996 May; No. 171():2 p. PubMed ID: 11660322
    [No Abstract]   [Full Text] [Related]  

  • 16. Obstetrician-gynecologists' ethical responsibilities, concerns, and risks pertaining to adoption. ACOG Committee Opinion No. 194.
    American College of Obstetricians and Gynecologists. Committee on Ethics
    ACOG Comm Opin; 1997 Nov; No. 194():4 p. PubMed ID: 11660574
    [No Abstract]   [Full Text] [Related]  

  • 17. ACOG Committee Opinion No. 401: Relationships with industry.
    American College of Obstetricians and Gynecologists Committee on Ethics
    Obstet Gynecol; 2008 Mar; 111(3):799-804. PubMed ID: 18310391
    [No Abstract]   [Full Text] [Related]  

  • 18. University-industry relationships in genetic research: potential opportunities and pitfalls.
    Walsh ME; Graber GC; Wolfe AK
    Account Res; 1997; 5(4):265-82. PubMed ID: 11656993
    [No Abstract]   [Full Text] [Related]  

  • 19. Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts.
    Brand R
    State Legis; 2008 Sep; 34(8):26-9. PubMed ID: 18754159
    [No Abstract]   [Full Text] [Related]  

  • 20. Sexual misconduct in the practice of obstetrics and gynecology: ethical considerations. ACOG Committee Opinion No. 144.
    American College of Obstetricians and Gynecologists. Committee on Ethics
    ACOG Comm Opin; 1994 Nov; No. 144():3 p. PubMed ID: 11660417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.